Boehringer Ingelheim
My giotrif logo

Afatinib
Afatinib

Read more

GIOTRIF® provides ≥3 years long-term response even with dose modification

14/07/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-102595

Long-term responders (LTRs) to targeted therapeutics, remain on therapy for prolonged periods and show improved tumour responses.5 Identifying and determining the patient or tumour characteristics of this subset of patients is useful.
A post-hoc analysis of the LUX-Lung 3, 6 and 7 trials identified a subset of patients who received ≥3 years of GIOTRIF® treatment as LTRs.5

Patients treated for at least 2, 2.5 and 3 years in the Overall LL3/6/7 populations5

  • 10% patients in LL3 and LL6 and 12% patients in LL7 were identified as LTRs5

  • The proportion of LTRs was higher with GIOTRIF® (12%) vs gefitinib (4%) in LL75

Long-term GIOTRIF® treatment was independent of tolerability-guided dose adjustment5

  • A majority of the LTRs underwent tolerability-guided dose adjustments and yet could obtain sustained clinical benefit with GIOTRIF®5

  • Median (range) duration of treatment was 50 (41-73) months in LL3, 56 (37-68) months in LL6 and 42 (37-50) months in LL75

  • 75% (18/24) of LTRs in LL3 had tolerability-guided dose reduction of afatinib to <40 mg/day

  • mPFS was 49.5 months in LL3, mOS not reached with a median follow-up time of 64.6 months

Efficacy

MYGIO2022COM||GIOTRIF® provides ≥3 years long-term response even with dose modification
MYBIONEGIO2022||South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
SEREAL||First-line GIOTRIF® data in over 30 real-world studies to-date
GIOTRIF® safety and effectiveness in the real world
Real-world evidence: GIOTRIF® in Japan
MYSEREAL||Real-world evidence: GIOTRIF® in Taiwan
Video: Uncommon EGFR pooled analysis in 693 patients
Real-world evidence: GIOTRIF® in South Korea
SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan
RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan
SEREAL||GIOTRIF® RWE in patients with brain metastases
SEREAL||Impact of GIOTRIF® in delaying CNS progression
SEREAL||GIOTRIF® RWE in Taiwan
SEREAL||GIOTRIF® efficacy in the real-world
SEREAL||GIOTRIF® in LUX-Lung 7
MYGIO2022COM||GIOTRIF® in elderly
MYBIONEGIO2022||GIOTRIF® in uncommon EGFR mutations
RWDRI||GIOTRIF® in Uncommon Mutation - A database analysis of >1000 NSCLC Patients

References

1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

2. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.

3. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.

4. Park K et al. Lancet Oncol 2016;17(5):577–89.

5. Schuler M, et al. Lung Cancer. 2019;133:10-19.

Footnotes

  • EGFR M+=epidermal growth factor receptor mutation positive; LTR = long-term responder; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival; LL3 = LUX-Lung 3; LL6 = LUX-Lung 6; LL7 = LUX-Lung 7.

  • * LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).

RELATED CONTENT